Id: acc2548
Group: 1sens
Protein: VASP
Gene Symbol: VASP
Protein Id: P50552
Protein Name: VASP_HUMAN
PTM: phosphorylation
Site: Ser239
Site Sequence: IAGAKLRKVSKQEEASGGPTA
Disease Category: Cancer
Disease: Lung Cancer
Disease Subtype:
Disease Cellline:
Disease Info:
Drug: Baicalein
Drug Info: -
Effect: promote
Effect Info: Drugs phosphorylate proteins and inhibit tumor metastasis.
Note:
Score: 5.0
Pubmed(PMID): 25268843
Sentence Index:
Sentence:

Sequence & Structure:

MSETVICSSRATVMLYDDGNKRWLPAGTGPQAFSRVQIYHNPTANSFRVVGRKMQPDQQVVINCAIVRGVKYNQATPNFHQWRDARQVWGLNFGSKEDAAQFAAGMASALEALEGGGPPPPPALPTWSVPNGPSPEEVEQQKRQQPGPSEHIERRVSNAGGPPAPPAGGPPPPPGPPPPPGPPPPPGLPPSGVPAAAHGAGGGPPPAPPLPAAQGPGGGGAGAPGLAAAIAGAKLRKVSKQEEASGGPTAPKAESGRSGGGGLMEEMNAMLARRRKATQVGEKTPKDESANQEEPEARVPAQSESVRRPWEKNSTTLPRMKSSSSVTTSETQPCTPSSSDYSDLQRVKQELLEEVKKELQKVKEEIIEAFVQELRKRGSP

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
VASP-Ser239
Cancer Intensity
BRCA 0.323
COAD -0.129
HGSC 2.013
ccRCC
GBM
HNSC
LUAD -0.555
LUSC -1.048
non_ccRCC -0.646
PDAC 0.041
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 239 D Esophageal squamous cell carcinoma Phosphorylation 32200035

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM
Protein Gene PTM Position Modified sequence Cell Drug pEC50 Regulation Experiment
P50552 VASP P Ser239 KVS(ph)KQEEASGGPTAPK A431 Afatinib 8.0926 -
P50552 VASP P Ser239 KVS(ph)KQEEASGGPTAPK A431 Afatinib 8.1102 -
P50552 VASP P Ser239 KVS(ph)KQEEASGGPTAPK A431 Afatinib 8.7616 -
P50552 VASP P Ser239 KVS(ph)KQEEASGGPTAPK A431 Afatinib 8.1733 -
P50552 VASP P Ser239 KVS(ph)KQEEASGGPTAPK A431 Dasatinib 6.1355 -
P50552 VASP P Ser239 KVS(ph)KQEEASGGPTAPK A431 Dasatinib 6.2604 -
P50552 VASP P Ser239 KVS(ph)KQEEASGGPTAPK A431 Dasatinib 7.2454 -
P50552 VASP P Ser239 KVS(ph)KQEEASGGPTAPK A431 Gefitinib 4.6401 -
P50552 VASP P Ser239 KVS(ph)KQEEASGGPTAPK A431 Gefitinib 7.0765 -
P50552 VASP P Ser239 KVS(ph)KQEEASGGPTAPK A431 Gefitinib 7.2789 -
P50552 VASP P Ser239 KVS(ph)KQEEASGGPTAPK A431 Gefitinib 7.0898 -
P50552 VASP P Ser239 KVS(ph)KQEEASGGPTAPK KYSE-520 SHP099 5.2468 -
P50552 VASP P Ser239 KVS(ph)KQEEASGGPTAPK RPMI8226 BTZ 9.3272 -
P50552 VASP P Ser239 KVS(ph)KQEEASGGPTAPK RPMI8226 BTZ 7.4838 -

pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.

Function score:

source: funscoR

No data.

Cross Links: